Biontech Se ADR BNTX

$98.30 -0.27 (-0.27%)

Valuation

Market cap
24,926,776,000
Revenue TTM
$3,247,010,000
Net income TTM
$-1,285,380,000
PE ratio
0.00
Forward PE
—
Profit margin
-39.59%
Debt to equity
0.02

Trading

Volume
845,500
Avg volume
1,246,090
Day's range
$96.90 – $99.14
Shares out
252,884,000
Stochastic %K
40%
Beta
1.29
Analysts
Strong Sell
Price target
$122.44

Price

Company profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast...

Show more

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Industry
Biotechnology
Sector
Healthcare
Phone
49 6131 9084
Website
https://www.biontech.de
Address
An der Goldgrube 12, Mainz, Germany

Latest news

Stocktwits

Estimize Oct 1, 11:03 AM
Wall St is expecting 0.85 EPS for $BNTX Q3 [Reporting 11/03 BMO] http://www.estimize.com/intro/bntx?chart=historical&metric_name=eps&utm_co
0 replies
Samishere Sep 30, 10:38 PM
$BNTX $MRNA $PFE
0 replies
taxplanr Sep 30, 1:41 PM
From Synthetic DNA and RNA-Based Self-Assembling Nanotechnology to Sequelae of COVID-19 Shots $PFE $BNTX $MRNA peer reviewed https://ijvtpr.com/index.php/IJVTPR/article/view/129
0 replies
Sergey_stockdoc Sep 30, 12:00 PM
$BNTX LOL this stock didn’t even go up with Moderna, and it’s likely to drop today with it. Like I said previously, ADRs are treated differently, and that you all won’t get the same response as Moderna. Expect this to sideline for the next year or so.
0 replies
taxplanr Sep 29, 12:42 PM
$MRNA $PFE $BNTX
2 replies
Swift_Trades Sep 29, 3:11 AM
$BNTX $GERN $KOD $MRNA which one is next?
1 replies
BTC321 Sep 28, 12:27 PM
$NVAX wow, this is huge and a huge chance for novavax nuvaxovid !!! BioNTech $BNTX is closing three German sites – Marburg, Idar-Oberstein, Tübingen – 1,800 jobs. Marburg was the plant that made most of Europe's Comirnaty mRNA drug substance, over a billion doses a year at peak. They couldn't find a buyer for it. That's tough news for the people there, and it's the clearest statement yet about where mRNA COVID vaccine demand has gone. The COVID vaccine market is smaller now, for everyone. What matters in a smaller market is share – and share is moving toward the option people tolerate better. Nuvaxovid: lowest reactogenicity of nine vaccines in the independent PICOBOO trial, better tolerated than mNEXSPIKE in Sanofi's head-to-head, approved in the US, EU and Japan on the same day. Sanofi is marketing it, Takeda is making it, and Novavax gets paid on every dose without owning a single plant to close. That's the difference between a factory and a royalty. NFA. Long $NVAX.
2 replies
Samishere Sep 27, 2:28 AM
$BNTX
0 replies